Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice

RenalytixAI and University Medical Center Groningen to Evaluate KidneyIntelX™ for Early Identification and Guiding Therapeutic Treatment of Diabetic Kidney Disease

NEW YORK, May 7, 2019 /PRNewswire/ —  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate  KidneyIntelX™  across over 3,500

Read More

Published
Categorized as News

FDA Grants Breakthrough Device Designation to KidneyIntelX™

Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ —  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted

Read More

Published
Categorized as News


Well Filtered™

Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.